Metaxalone

Identification

Name
Metaxalone
Accession Number
DB00660  (APRD00514)
Type
Small Molecule
Groups
Approved
Description

Metaxalone (marketed by King Pharmaceuticals under the brand name Skelaxin®) is a muscle relaxant used to relax muscles and relieve pain caused by strains, sprains, and other musculoskeletal conditions. Its exact mechanism of action is not known, but it may be due to general central nervous system depression. It is considered to be a moderately strong muscle relaxant, with relatively low incidence of side effects. Skelaxin comes in an 800 mg scored tablet. It previously came in both 400 mg and 800 mg tablets. The 400 mg tablet has been discontinued. Possible side effects include nausea, vomiting, drowsiness and CNS side effects such as dizziness, headache, and irritability.

Structure
Thumb
Synonyms
  • Metassalone
  • Metaxalon
  • Metaxalona
  • Metaxalonum
External IDs
AHR 438
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MetaxaloneTablet800 mg/1OralCarilion Materials Management2007-11-01Not applicableUs
MetaxaloneTablet800 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2011-12-06Not applicableUs
MetaxaloneTablet800 mg/1OralA S Medication Solutions2007-11-012017-06-20Us
MetaxaloneTablet800 mg/1OralH.J. Harkins Company2007-11-01Not applicableUs
MetaxaloneTablet800 mg/1OralUnit Dose Services2007-11-01Not applicableUs
MetaxaloneTablet800 mg/1OralStat Rx USA2007-11-01Not applicableUs
MetaxaloneTablet800 mg/1OralPreferreed Pharmaceuticals Inc.2014-02-14Not applicableUs
MetaxaloneTablet800 mg/1OralPd Rx Pharmaceuticals, Inc.2007-11-01Not applicableUs64720 0321 10 nlmimage10 6108b0b5
MetaxaloneTablet800 mg/1Oralbryant ranch prepack2007-11-01Not applicableUs
MetaxaloneTablet800 mg/1OralNorthwind Pharmaceuticals2014-04-01Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MetaxallTablet800 mg/1OralSircle Laboratories, Llc2015-09-25Not applicableUs
MetaxaloneTablet800 mg/1OralAmneal Pharmaceuticals2013-05-31Not applicableUs
MetaxaloneTablet800 mg/1OralSolis Generic Pharmaceuticals Llc2016-10-21Not applicableUs
MetaxaloneTablet800 mg/1OralRed Pharm Drug, Inc.2013-05-31Not applicableUs
MetaxaloneTablet800 mg/1OralEon Labs, Inc.2010-03-31Not applicableUs
MetaxaloneTablet800 mg/1OralAidarex Pharmaceuticals LLC2013-05-31Not applicableUs
MetaxaloneTablet800 mg/1OralClinical Solutions Wholsesale2013-05-312017-06-24Us
MetaxaloneTablet800 mg/1OralRemedy Repack2017-10-09Not applicableUs
MetaxaloneTablet800 mg/1OralGemini Pharmaceuticals, Inc.2015-12-30Not applicableUs
MetaxaloneTablet800 mg/1OralA S Medication Solutions2013-05-312017-06-20Us
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MetaxaloneTablet800 mg/1OralRemedy Repack2017-11-02Not applicableUs
MetaxaloneTablet800 mg/1OralSt. Marys Medical Park Pharmacy2017-06-19Not applicableUs
International/Other Brands
Skelaxin
Categories
UNII
1NMA9J598Y
CAS number
1665-48-1
Weight
Average: 221.2524
Monoisotopic: 221.105193351
Chemical Formula
C12H15NO3
InChI Key
IMWZZHHPURKASS-UHFFFAOYSA-N
InChI
InChI=1S/C12H15NO3/c1-8-3-9(2)5-10(4-8)15-7-11-6-13-12(14)16-11/h3-5,11H,6-7H2,1-2H3,(H,13,14)
IUPAC Name
5-(3,5-dimethylphenoxymethyl)-1,3-oxazolidin-2-one
SMILES
CC1=CC(OCC2CNC(=O)O2)=CC(C)=C1

Pharmacology

Indication

For the treatment of painful peripheral musculoskeletal conditions and spasticity from upper motor neuron syndromes.

Structured Indications
Pharmacodynamics

Metaxalone is a skeletal muscle relaxant indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Metaxalone does not directly relax tense skeletal muscles in man.

Mechanism of action

The mechanism of action of metaxalone in humans has not been established, but may be due to general central nervous system depression.

Absorption

The absolute bioavailability of metaxalone from Skelaxin tablets is not known.

Volume of distribution
  • 800 L
Protein binding
Not Available
Metabolism

Probably hepatic.

Route of elimination

Metaxalone is metabolized by the liver and excreted in the urine as unidentified metabolites.

Half life

9.2 (+/- 4.8) hours

Clearance
  • 68 +/- 50 L/h [Subjects received 1×400mg tablet under fasted conditions]
  • 66 +/- 51 L/h [Subjects received 2×400 mg tablets under fasted conditions]
Toxicity

LD50=775mg/kg (Rat, oral); LD50=1690 mg/kg (Mouse, oral). When determining the LD50 in rats and mice, progressive sedation, hypnosis and finally respiratoryfailure were noted as the dosage increased. In dogs, no LD50 could be determined as the higher doses produced an emetic action in 15 to 30 minutes.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Metaxalone.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Metaxalone.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Metaxalone.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Metaxalone.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Metaxalone.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Metaxalone is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Metaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Metaxalone.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Metaxalone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Metaxalone.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Metaxalone.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Metaxalone.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Metaxalone.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Metaxalone.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Metaxalone.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Metaxalone.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Metaxalone.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Metaxalone.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Metaxalone.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Metaxalone.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Metaxalone.Investigational, Vet Approved
AzelastineMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Metaxalone.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Metaxalone.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Metaxalone.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Metaxalone.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Metaxalone.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Metaxalone is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Metaxalone.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Metaxalone.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Metaxalone.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Metaxalone.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Metaxalone.Approved, Investigational
BuprenorphineMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Metaxalone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Metaxalone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Metaxalone.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Metaxalone.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Metaxalone.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Metaxalone.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Metaxalone.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Metaxalone.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Metaxalone.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Metaxalone.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Metaxalone.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Metaxalone.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Metaxalone.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Metaxalone.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Metaxalone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Metaxalone.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Metaxalone.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Metaxalone.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Metaxalone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Metaxalone.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Metaxalone is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Metaxalone.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Metaxalone is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Metaxalone.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Metaxalone.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Metaxalone is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Metaxalone.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Metaxalone.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Metaxalone.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Metaxalone.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Metaxalone.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Metaxalone.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Metaxalone.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Metaxalone.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Metaxalone.Approved
DantroleneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Metaxalone.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Metaxalone.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Metaxalone.Approved
DesipramineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Metaxalone.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Metaxalone.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Metaxalone.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Metaxalone.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Metaxalone.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Metaxalone.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Metaxalone.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Metaxalone.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Metaxalone is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Metaxalone.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Metaxalone.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Metaxalone.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Metaxalone is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Metaxalone.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Metaxalone.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Metaxalone.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Metaxalone.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Metaxalone is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Metaxalone.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Metaxalone.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Metaxalone.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Metaxalone.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Metaxalone.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Metaxalone.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Metaxalone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Metaxalone.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Metaxalone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Metaxalone is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Metaxalone.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Metaxalone.Approved
EthanolMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Metaxalone.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Metaxalone.Approved
EthotoinThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Metaxalone.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Metaxalone.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Metaxalone.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Metaxalone.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Metaxalone.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Metaxalone.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Metaxalone.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Metaxalone.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Metaxalone.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Metaxalone is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Metaxalone.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Metaxalone.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Metaxalone is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Metaxalone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Metaxalone.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Metaxalone.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Metaxalone.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Metaxalone.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Metaxalone.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Metaxalone.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Metaxalone.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Metaxalone.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Metaxalone is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Metaxalone.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Metaxalone.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Metaxalone is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Metaxalone.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Metaxalone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Metaxalone.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Metaxalone.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Metaxalone.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Metaxalone.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Metaxalone.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Metaxalone.Approved
HydrocodoneMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Metaxalone.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Metaxalone.Approved
IndalpineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Metaxalone.Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Metaxalone.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Metaxalone.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Metaxalone.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Metaxalone.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Metaxalone.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Metaxalone is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Metaxalone.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Metaxalone is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Metaxalone.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Metaxalone is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Metaxalone.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Metaxalone.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Metaxalone.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Metaxalone.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Metaxalone.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Metaxalone.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Metaxalone.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Metaxalone.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Metaxalone.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Metaxalone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Metaxalone.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Metaxalone.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Metaxalone.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Metaxalone.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Metaxalone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Metaxalone.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Metaxalone.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Metaxalone.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Metaxalone.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Metaxalone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Metaxalone.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Metaxalone.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Metaxalone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Metaxalone.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Metaxalone.Approved
MethotrimeprazineMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Metaxalone.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Metaxalone is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Metaxalone.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Metaxalone.Approved
MetyrosineMetaxalone may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Metaxalone.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Metaxalone is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved, Investigational
MirtazapineMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Metaxalone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Metaxalone.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Metaxalone.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Metaxalone.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Metaxalone.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Metaxalone.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Metaxalone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Metaxalone.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Metaxalone.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Metaxalone.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Metaxalone.Approved, Illicit
OrphenadrineMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Metaxalone.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Metaxalone.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Metaxalone.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Metaxalone.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Metaxalone.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Metaxalone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Metaxalone.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Metaxalone.Approved
ParaldehydeMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Metaxalone.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Metaxalone.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Metaxalone.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Metaxalone.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Metaxalone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Metaxalone.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Metaxalone.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Metaxalone.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Metaxalone.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Metaxalone.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Metaxalone.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Metaxalone.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Metaxalone.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Metaxalone.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Metaxalone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Metaxalone.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Metaxalone is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Metaxalone is combined with Pomalidomide.Approved
PramipexoleMetaxalone may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Metaxalone.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Metaxalone.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Metaxalone.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Metaxalone.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Metaxalone.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Metaxalone.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Metaxalone.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Metaxalone.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Metaxalone.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Metaxalone.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Metaxalone.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Metaxalone.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Metaxalone.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Metaxalone.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Metaxalone.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Metaxalone.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Metaxalone.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Metaxalone.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Metaxalone.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Metaxalone.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Metaxalone.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Metaxalone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Metaxalone.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Metaxalone.Vet Approved
RopiniroleMetaxalone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Metaxalone.Approved
RotigotineMetaxalone may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Metaxalone.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Metaxalone.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Metaxalone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Metaxalone.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Metaxalone.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved
StiripentolThe risk or severity of adverse effects can be increased when Metaxalone is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Metaxalone.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Metaxalone.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Metaxalone.Experimental
SuvorexantMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Metaxalone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Metaxalone.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Metaxalone.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Metaxalone.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Metaxalone.Investigational
ThalidomideMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Metaxalone.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Metaxalone.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Metaxalone.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Metaxalone.Approved
TiagabineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Metaxalone.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Metaxalone.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Metaxalone.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Metaxalone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Metaxalone.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Metaxalone.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Metaxalone.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Metaxalone.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Metaxalone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Metaxalone.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Metaxalone.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Metaxalone.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Metaxalone.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Metaxalone.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Metaxalone.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Metaxalone.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Metaxalone.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Metaxalone.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Metaxalone is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Metaxalone.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Metaxalone.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Metaxalone.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Metaxalone.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Metaxalone.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Metaxalone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Metaxalone.Vet Approved
ZolpidemMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Metaxalone is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Metaxalone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Metaxalone.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Metaxalone.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Spiridon Spireas, "Bioavailable compositions of metaxalone and processes for producing the same." U.S. Patent US20050276844, issued December 15, 2005.

US20050276844
General References
  1. See S, Ginzburg R: Choosing a skeletal muscle relaxant. Am Fam Physician. 2008 Aug 1;78(3):365-70. [PubMed:18711953]
  2. Elenbaas JK: Centrally acting oral skeletal muscle relaxants. Am J Hosp Pharm. 1980 Oct;37(10):1313-23. [PubMed:6999895]
External Links
Human Metabolome Database
HMDB14798
KEGG Drug
D00773
KEGG Compound
C07934
PubChem Compound
15459
PubChem Substance
46506253
ChemSpider
14709
ChEBI
6797
ChEMBL
CHEMBL1079604
PharmGKB
PA164747189
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Metaxalone
FDA label
Download (124 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4RecruitingTreatmentLow Back Pain (LBP)1

Pharmacoeconomics

Manufacturers
  • Sandoz inc
  • King pharmaceuticals inc
  • Elan Corporation
Packagers
Dosage forms
FormRouteStrength
TabletOral400 mg/1
TabletOral800 mg/1
Prices
Unit descriptionCostUnit
Metaxalone 800 mg tablet3.88USD tablet
Skelaxin 800 mg tablet3.84USD tablet
Skelaxin 400 mg tablet0.84USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6407128No2001-12-032021-12-03Us
US7122566No2006-02-062026-02-06Us
US7714006No2001-12-032021-12-03Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)122 °CPhysProp
logP2.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.28 mg/mLALOGPS
logP1.63ALOGPS
logP2.37ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)13.14ChemAxon
pKa (Strongest Basic)-4.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area47.56 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity59.32 m3·mol-1ChemAxon
Polarizability23.74 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9747
Caco-2 permeable+0.5076
P-glycoprotein substrateNon-substrate0.7072
P-glycoprotein inhibitor INon-inhibitor0.8309
P-glycoprotein inhibitor IINon-inhibitor0.906
Renal organic cation transporterNon-inhibitor0.8464
CYP450 2C9 substrateNon-substrate0.8154
CYP450 2D6 substrateNon-substrate0.7182
CYP450 3A4 substrateNon-substrate0.5649
CYP450 1A2 substrateInhibitor0.6863
CYP450 2C9 inhibitorNon-inhibitor0.7448
CYP450 2D6 inhibitorNon-inhibitor0.7733
CYP450 2C19 inhibitorNon-inhibitor0.6471
CYP450 3A4 inhibitorNon-inhibitor0.911
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.797
Ames testNon AMES toxic0.6074
CarcinogenicityNon-carcinogens0.9312
BiodegradationNot ready biodegradable0.9544
Rat acute toxicity2.4250 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9319
hERG inhibition (predictor II)Non-inhibitor0.913
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00di-0490000000-964e6b5348bafc1182d9
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0089-0980000000-2b6e14f3b5e5c19c4e5c
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-001i-0910000000-c8b21539b07eb2e7d34e
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-001i-0900000000-0f09eb181838526daa7c
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-001i-0900000000-018693fc5b6345ee25c5
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-001i-0900000000-921f9f6e188e7466aa4d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-08fr-4900000000-222616eabf1bcdd48049
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-08fr-6900000000-06981ad91bcbeda7d385
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-6900000000-77e22c24cb4c6bbc81a1
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-8900000000-54c62bf2b5c1b70898bb
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-9700000000-82878fa5fbb78b27ef0b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-9500000000-66f674cba4e44834a425

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenol ethers
Sub Class
Not Available
Direct Parent
Phenol ethers
Alternative Parents
m-Xylenes / Phenoxy compounds / Alkyl aryl ethers / Oxazolines / Propargyl-type 1,3-dipolar organic compounds / Oxacyclic compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Hydrocarbon derivatives
Substituents
Phenoxy compound / M-xylene / Xylene / Phenol ether / Alkyl aryl ether / Monocyclic benzene moiety / Oxazoline / Ether / Propargyl-type 1,3-dipolar organic compound / Organic 1,3-dipolar compound
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
aromatic ether (CHEBI:6797)

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:41